User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Bibliographic reference Machiels, Jean-Pascal ; Haddad, Robert I ; Fayette, Jérôme ; Licitra, Lisa F ; Tahara, Makoto ; et. al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. In: The Lancet Oncology, Vol. 16, no.5, p. 583-594 (2015)
Permanent URL http://hdl.handle.net/2078.1/162698